%0杂志文章%@ 1438- 8871% I JMIR出版物%V 19卡塔尔世界杯8强波胆分析% N 5% P e154% T移动应用程序治疗应激性尿失禁:A成本-效益分析%A Sjöström,Malin %A Lindholm,Lars %A Samuelsson,Eva %+公共卫生和临床医学系，Umeå大学，地区Jämtland Härjedalen, Box 654, Umeå， SE-832 27，瑞典，46 703269948,malin.sjostrom@regionjh.se %K移动应用%K盆底%K尿失检，压力%K自我护理%K成本-效益分析%D 2017 %7 08.05.2017 %9原始论文%J J医学互联网Res %G英文%X背景:移动应用程序可以增加获得护理的机会，促进自我管理，并提高对治疗的依从性。压力性尿失禁(SUI)影响了10-35%的女性，目前，一款提供盆底肌肉训练(PFMT)指导的应用程序可作为一线治疗方法。之前的一项随机对照研究表明，该应用程序有利于症状严重程度和生活质量(QoL);在本研究中，我们调查了应用程序的成本效益。目的:本研究的目的是评估应用程序治疗SUI的健康经济。方法:这种确定性的成本效用分析，从1年的社会视角，比较应用程序治疗和不治疗。健康经济数据与2013年3月至2014年10月在瑞典进行的随机对照试验一起收集。本研究包括123名18岁及以上的社区女性参与者，每周压力性尿失禁≥1次。参与者通过有效的问卷和2天渗漏日记进行自我评估，然后随机分为3个月的治疗(app组，n=62)或不治疗(对照组，n=61)。 The app focused on pelvic floor muscle training, prescribed 3 times daily. We continuously registered treatment delivery costs. Data were collected on each participant’s training time, incontinence aids, and laundry at baseline and at a 3-month follow-up. We measured quality of life with the International Consultation on Incontinence Modular Questionnaire on Lower Urinary Tract Symptoms and Quality of Life, and calculated the quality-adjusted life years (QALYs) gained. Data from the 3-month follow-up were extrapolated to 1 year for the calculations. Our main outcome was the incremental cost-effectiveness ratios compared between app and control groups. One-way and multiway sensitivity analyses were performed. Results: The mean age of participants was 44.7 years (SD 9.4). Annual costs were €547.0 for the app group and €482.4 for the control group. Annual gains in quality-adjusted life years for app and control groups were 0.0101 and 0.0016, respectively. Compared with controls, the extra cost per quality-adjusted life year for the app group ranged from −€2425.7 to €14,870.6, which indicated greater gains in quality-adjusted life years at similar or slightly higher cost. Conclusions: The app for treating stress urinary incontinence is a new, cost-effective, first-line treatment with potential for increasing access to care in a sustainable way for this patient group. %M 28483745 %R 10.2196/jmir.7383 %U //www.mybigtv.com/2017/5/e154/ %U https://doi.org/10.2196/jmir.7383 %U http://www.ncbi.nlm.nih.gov/pubmed/28483745